While Verteporfin can effectively disrupt YAP/TAZ interaction with TEADs [56], other effects for this drug have been described, such as inhibition of autophagosome formation [116,117], thus making it not so suitable for use as a specific YAP/TAZ transcriptional inhibitor in cancer. Here, YAP1 is linked to cancer.